Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNBELIEVABLE: Karyopharm - Caught on Camera

Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts

Karyopharm Therapeutics (NASDAQ:KPTI) executives used an H.C. Wainwright BioConnect Conference appearance to highlight upcoming clinical and regulatory milestones for selinexor, the company’s oral nuclear export inhibitor marketed as XPOVIO in multiple myeloma. Chief Executive Officer Richard Pauls

Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus

Karyopharm Therapeutics (NASDAQ:KPTI) executives said the company expects to provide a fuller presentation of its Phase 3 SENTRY trial data for selinexor in myelofibrosis at the upcoming ASCO conference, while also outlining expected regulatory engagement and other development priorities during a re

Karyopharm Therapeutics Q1 Earnings Call Highlights

Karyopharm Therapeutics (NASDAQ:KPTI) said it entered 2026 with several near-term clinical and regulatory catalysts, led by new Phase 3 data in myelofibrosis and an expected midyear readout in endometrial cancer, while reporting higher first-quarter revenue and reaffirming full-year guidance. On th

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Wednesday announced comprehensive financing and capital structure transactions expected to provide the company with $100 million of financial flexibility and additional capital, extending the cash runway into the second quarter of 2026.

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement

Biogen Inc. (NASDAQ:BIIB) has informed Karyopharm Therapeutics Inc (NASDAQ:KPTI) that it has opted to terminate the companies' Asset Purchase Agreement dated January 24, 2018, as amended. As per the agreement, Karyopharm sold rights of its oral Selective Inhibitor of Nuclear Export compound KPT-350 and certain related assets to Biogen. KPTI received an upfront payment…

The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi

Here's a roundup of top developments in the biotech space over the last 24 hours.

inkl

Read news from The Economist, FT, and more,
with one subscription

Why Are Karyopharm Shares Trading Lower Today

Why Are Karyopharm Shares Trading Lower Today

Karyopharm Therapeutics Inc (NASDAQ: KPTI) stock plunged after an

Why Are Karyopharm Shares Plunging Today?

Why Are Karyopharm Shares Plunging Today?

Karyopharm Therapeutics Inc (NASDAQ: KPTI) revealed that executive vice president and chief medical officer Jatin Shah departs for "other professional opportunities."

Karyopharm Shares Fall After Selinexor Data In Endometrial Cancer Patients

Karyopharm Shares Fall After Selinexor Data In Endometrial Cancer Patients

Karyopharm Therapeutics Inc's (NASDAQ: KPTI) Phase 3 SIENDO selinexor study has

1

Organisations

European Commission

Rhythm Pharmaceuticals

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Endometrial Cancer

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

416,347 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play